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ABSTRACT	
Most	human	proteins	possess	amyloidogenic	segments,	but	only	about	
30	are	associated	to	amyloid-associated	pathologies	and	it	remains	unclear	
what	determines	amyloid	toxicity.	We	here	designed	vascin,	a	synthetic	
amyloid	peptide,	based	on	an	amyloidogenic	fragment	of	VEGFR2,	a	protein	
that	is	not	associated	to	amyloidosis.	Vascin	recapitulates	key	biophysical	and	
biochemical	characteristics	of	natural	amyloids,	penetrates	cells	and	seeds	the	
aggregation	of	VEGFR2	by	direct	interaction.	We	find	that	amyloid	toxicity	is	
observed	only	in	cells	that	both	express	VEGFR2	and	are	dependent	on	VEGFR2	
activity	for	survival.	Thus	amyloid	toxicity	here	appears	to	be	both	protein	
specific	and	conditional,	i.e.	determined	by	VEGFR2	loss-of-function	in	a	
biological	context	where	target	protein	function	is	essential.	
	
INTRODUCTION	
Amyloid	aggregation	of	proteins	is	driven	by	short	amyloidogenic	sequence	
segments	within	a	protein	chain	(1,	2)	that	have	the	potential	to	self-assemble	into	b-
sheet	ribbons	to	form	the	characteristic	cross-beta	structured	spine	of	amyloid	
structures	(3,	4).	It	has	been	shown	that	most	proteins	do	in	fact	possess	such	
amyloidogenic	sequence	segments	(5,	6).	Still,	only	about	30	human	proteins	are	
known	to	be	involved	in	amyloid-associated	diseases	(7,	8).	Moreover	it	is	still	not	
clear	what	determines	amyloid	toxicity	in	these	diseases	(8,	9).	Here	we	investigate	
whether	an	endogenously	expressed	protein	that	possesses	amyloidogenic	potential	
but	aggregates	neither	under	normal	nor	pathological	conditions,	can	be	induced	to	
do	so	by	seeding	with	a	peptide	consisting	of	an	amyloidogenic	fragment	of	its	own	
sequence.	The	use	of	amyloidogenic	fragment	peptides	is	motivated	by	the	
observation	that	aggregation	of	disease–associated	amyloidogenic	proteins	can	be	
seeded	by	such	peptides	in	vitro	(10,	11)	and	that	truncations	of	amyloid	proteins	
have	been	associated	with	increased	seeding	potential	in	vivo	(12,	13).	Moreover	it	
has	been	shown	that	amyloidogenic	peptides	and	proteins	are	generally	much	more	
efficient	at	seeding	aggregation	of	homotypic	sequences	(14-16)	although	examples	
of	cross	seeding	do	exist	(17-19).	Indeed,	seeding	of	protein	aggregation	in	vitro	
appears	to	work	universally,	and	fits	with	the	structural	model	of	aggregation	as	the	
addition	of	new	strands	to	a	growing	amyloid	fibril	(8).	This	imparts	sequence	
	 	 Design	of	a	biologically	active	amyloid	
	 	 Page	4/29	
specificity	to	the	seeding	process	as	the	incorporation	of	non-homologous	sequences	
into	the	highly	ordered	in-register	stacking	of	identical	side	chains	in	the	fibril	core	is	
likely	to	be	energetically	disfavoured	(13,	20,	21).	The	seeding	concept	appears	to	
hold	true	both	in	cell	culture	and	in	vivo,	even	for	non-prion	aggregation-associated	
peptides	and	proteins,	which	have	hence	been	called	prionoids	(22).	As	a	target	
protein	we	choose	VEGFR2	as	the	function	of	this	protein	is	well	characterized.	To	
ensure	efficient	seeding	we	designed	an	amyloidogenic	peptide	termed	vascin	
consisting	of	a	tandem	repeat	of	an	amyloidogenic	sequence	segment	in	the	VEGFR2	
signal	peptide.		
We	find	that	vascin	is	a	bona	fide	amyloidogenic	peptide	that	forms	mature	
cross-beta	fibrils	along	with	prefibrillar	intermediates	including	soluble	oligomers	
and	protofibrils.	Moreover	we	find	that	the	peptide	is	able	to	enter	cells	and	reach	
the	cytoplasmic	compartment	and	specifically	induce	the	aggregation	of	endogenous	
VEGFR2	thereby	inhibiting	its	function	in	Human	Umbilical	Vein	Endothelial	Cells	
(HUVEC)	in	vitro	and	reducing	VEGFR2-dependent	tumor	progression	in	vivo.			
It	remains	unclear	what	determines	amyloid	toxicity	in	amyloid	diseases	and	
whether	cell	death	results	from	a	consequence	of	direct	amyloid	toxicity	(gain-of-
function)	or	whether	it	is	a	consequence	of	loss-of-function	(23,	24).	However,	our	
detailed	understanding	of	real	amyloid	disease	models	is	often	insufficient	to	address	
these	questions	directly.	Indeed	for	many	disease	associated	amyloidogenic	proteins	
–such	as	the	Ab	peptide	in	Alzheimer	disease	(25)	and	a-synuclein	in	Parkinson	
disease	(26)-	we	still	have	insufficient	understanding	both	of	their	physiological	role	
as	well	as	the	cellular	interactions	of	the	amyloid	conformation	in	disease	(26,	27).	
We	do	however	have	a	better	understanding	of	the	structural	and	biochemical	
characteristics	that	are	common	to	most	amyloid	diseases.	These	features	include	the	
cross-beta	structural	organization	of	the	spine	of	the	amyloid	fibrils	formed	by	short	
segments	of	the	sequence,	the	population	of	prefibrillar	intermediates	including	
soluble	oligomers	and	protofibrils,	and	the	capacity	of	amyloids	to	seed	aggregation	
of	the	native	conformation.	While	our	artificial	amyloid	model	recapitulates	these	
key	structural	and	biochemical	features	of	natural	amyloids,	it	is	also	simple	enough	
to	investigate	the	relationship	between	protein	loss-of-function	and	amyloid	toxicity.		
Our	results	show	that	vascin	amyloids	are	not	inherently	toxic	but	that	the	
emergence	of	amyloid	toxicity	is	dependent	on	biological	context.	Vascin	is	not	toxic	
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to	cells	that	do	not	express	VEGFR2	or	to	cells	expressing	VEGFR2	but	that	are	not	
dependent	on	VEGFR2	function.	However	when	introduced	in	VEGFR2	dependent	
cells	we	find	association	of	vascin	amyloid	toxicity	and	VEGFR2	loss-of-function.	Our	
model	system	therefore	demonstrates	that	amyloidogenic	protein	fragments	can	
induce	aggregation	of	non	amyloidogenic	proteins	and	that	under	these	conditions	
amyloid	gain	of	function	is	a	phenotypic	effect	resulting	from	cell	context	specific	
loss-of-function.		
	
RESULTS	
Design	of	vascin,	an	amyloidogenic	peptide	derived	from	a	VEGFR2	fragment	
We	analyzed	the	VEGFR2	proteins	from	mouse	and	human	using	the	statistical	
thermodynamics	algorithm	TANGO	(28)	(Figure	S1A).	Since	we	envisaged	testing	the	
sequence	ultimately	in	a	mouse	model,	we	opted	for	maximal	compatibility	with	the	
murine	protein.	Moreover,	the	two	homologs	share	84%	sequence	identity	overall	
and	90%	in	the	TANGO-regions.	To	derive	peptide	sequences	that	are	likely	to	form	
amyloid	structure	in	isolation,	but	also	have	a	high	potential	for	forming	soluble	
oligomers	(29),	we	devised	a	strategy	(30,	31)	that	makes	use	of	a	sequence	feature	
of	functional	amyloids	and	yeast	prions,	which	often	contain	several	Aggregation	
Prone	Regions	(APR)	(32)	closely	connected	by	disordered	regions	(33).	Hence	we	
placed	two	APRs	in	a	peptide,	separated	by	a	rigid	proline-proline	linker,	mimicking	
these	repeat	patterns.	In	order	to	maintain	colloidal	stability	and	solubility	of	the	
sequence,	we	supercharged	the	peptides	by	flanking	the	APRs	with	either	negatively	
charged	aspartate	or	positively	charged	arginine	residues.	Given	the	length	
limitations	imposed	by	the	efficiency	of	solid	phase	peptide	synthesis,	this	design	
scheme	imposes	a	length	limitation	on	the	APRs	of	7	amino	acids.	Hence	we	selected	
10	such	high	scoring	sequences	(Table	S1)	and	generated	the	38	peptide	sequences	
listed	in	Supplementary	Table	2,	which	explore	both	tandem	repeats	of	the	same	APR	
as	well	as	fusions	of	different	APRs.	Peptides	were	screened	for	their	ability	to	inhibit	
VEGF	signaling	in	HEK293	cells	transfected	with	mouse	VEGFR2.	To	this	end,	cells	
were	treated	overnight	with	an	apparent	concentration	of	20	µM	peptide	(assuming	
100%	synthesis	efficiency)	and	ERK	phosphorylation	was	determined	after	
stimulation	for	5	min	with	25	ng/mL	VEGF	(Figure	S1B).	At	this	concentration,	we	
observed	inhibition	only	with	2	peptides	(B8	and	B12).	The	effect	was	most	
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pronounced	with	the	peptide	B8,	which	was	based	on	a	tandem	repeat	of	the	first	
high	scoring	aggregation	prone	region	in	the	sequence	that	belongs	to	the	signal	
peptide	and	has	the	sequence	L6AVALWF12	(Figure	S2A),	resulting	in	the	sequence	
DLAVALWFDPPDLAVALWFD	(pI	=	3.38,	M.W.	=	2272.15	Da).	We	termed	this	peptide	
vascin	(Figure	S2B),	obtained	additional	material	by	solid	phase	peptide	synthesis	
followed	by	HPLC	purification	(Figure	S2C),	and	confirmed	its	identity	by	mass	
spectrometry	(observed	mass:	2272.4,	Figure	S2D).	
	
Vascin	forms	soluble	b-structured	oligomers	that	mature	into	amyloid	fibrils		
To	determine	the	amyloidogenic	nature	of	the	peptide,	vascin	was	dissolved	
to	a	final	concentration	of	300	µM	in	1%	(w/v)	ammonium	bicarbonate	in	ddH2O.	
After	24	hours	incubation	Transmission	Electron	Microscopy	(TEM)	revealed	typical	
amyloid	fibrils	of	about	10	nm	in	width	consisting	of	protofilaments	of	4-5	nm	
(Figure	1A-D	and	Figure	S3).	Additionally,	vascin	fibrils	bind	amyloid	sensor	dyes,	
including	Thioflavin-T	and	the	amyloid	specific	oligothiophene	h-HTAA	(34)	(Figure	
1E).	X-ray	diffraction	of	aligned	bundles	of	vascin	fibrils	confirmed	their	cross-beta	
nature,	with	characteristic	diffractions	at	4.7	and	10Å	(Figure	1F).	Together	these	
data	confirm	the	amyloidogenic	nature	of	vascin.	In	order	to	follow	amyloid	
formation	kinetics	we	filtered	100	µM	dissolved	vascin	1%	(w/v)	ammonium	
bicarbonate	in	ddH2O	through	a	0.2	µm	regenerated	cellulose	filter	and	monitored	
particle	size	distribution	using	electrospray	ionisation-mass	spectrometry	linked	to	
ion	mobility	spectrometry	(ESI-IMS-MS)(35)	(Figure	1G)	and	Dynamic	Light	
Scattering	(DLS)	(Figure	1H).	At	time	zero,	the	MS	resolved	a	mixture	of	monomers	
and	multimers	up	to	heptamers	(Figure	1G),	whereas	the	particle	sizes	estimated	
through	DLS	ranged	from	5-100	nm	(assuming	linear	polymer	particles).	This	
indicates	that	the	filtered	vascin	solution	contains	soluble	oligomeric	aggregates	
already	at	time	zero.	After	6	h	particles	reached	sizes	over	1	µm	(Figure	1H).	The	fact	
that	no	lag	phase	was	observed	in	the	evolution	of	the	DLS	autocorrelation	function	
(Figures	S4A	&	B)	further	suggests	that	these	soluble	oligomers	are	able	to	directly	
proceed	to	amyloid	fibril	formation.	In	order	to	probe	the	secondary	structure	of	
these	soluble	aggregates	we	monitored	the	same	aggregation	kinetics	using	Fourier	
Transform	Infra-Red	spectroscopy	(FT-IR).	The	spectrum	at	time	zero	was	
dominated	by	maxima	near	1630	and	1690	cm-1	(Figure	1I),	characteristic	of	b-sheet	
	 	 Design	of	a	biologically	active	amyloid	
	 	 Page	7/29	
structure.	Over	the	following	3h	the	intensity	of	these	peaks	increased	markedly	
while	the	center	of	the	peaks	shifted	gradually	to	1622	and	1692	cm-1,	respectively	
(Figure	1I&J).	These	peaks	were	quite	narrow	and	regions	outside	the	peaks	showed	
very	little	absorption,	suggesting	that	most	of	the	peptide	sequence	is	involved	in	b-
structured	hydrogen	bonding.	FT-IR	kinetics	therefore	indicate	that	vascin	largely	
adopts	a	b-structured	conformation	upon	solubilization	in	1%	ammonium	
bicarbonate	and	that	these	species	mature	into	amyloid	fibrils	over	time.	Finally,	we	
measured	binding	to	8-anilino-1-naphthalenesulphonic	acid	(ANS)	during	vascin	
amyloid	formation	(Figure	S4C),	revealing	high	binding	of	this	dye	at	time	zero.		The	
latter	is	a	typical	feature	of	interaction-prone	cytotoxic	prefibrillar	oligomers	that	
present	a	high	degree	of	solvent	exposed	hydrophobic	surface	(36).	The	binding	of	
ANS	increased	over	time,	suggesting	hydrophobic	surfaces	stay	exposed	upon	fibril	
formation.	We	also	verified	the	amyloidotypic	double	peak	fluorescence	spectrum	of	
vascin	with	the	LCO	hHTAA	in	contrast	to	the	scrambled	peptide	(Figure	S4D).	Given	
that	the	above	observations	were	made	at	300	µM	peptide	where	the	signal	to	noise	
ratio	for	biophysical	characterisation	is	optimal,	we	also	verified	that	vascin	readily	
formed	amyloid	fibrils	at	the	lower	concentration	of	30	µM	(Figure	S5).	Compared	to	
vascin	a	scrambled	version	of	the	peptide	(Note	S1)	formed	small	soluble	aggregates	
with	hydrodynamic	radii	smaller	than	100	nm	as	estimated	by	DLS	(Figure	S6A&B)	
that	exhibited	a	non-fibrillar	morphology	via	TEM	(Figure	S6C),	and	displayed	
marginal	affinity	for	the	amyloid	sensor	dyes	with	no	specific	emission	spectrum	for	
amyloid	fibers	(Figure	1E	and	S4D).	Similar	observations	were	made	with	a	vascin	
variant	in	which	proline	mutations	were	introduced	to	break	the	beta-sheet	
propensity	of	the	APRs	in	vascin	(Note	S2	and	Figure	S7).	In	contrast,	a	version	of	
vascin	based	on	the	human	sequence	(h.	vascin,	DLAVALWLDPPDLAVALWLD),	
containing	a	single	mutation	of	phenylalanine	to	leucine	at	position	7	of	the	APR,	
displayed	similar	amyloid	formation	as	the	original	mouse	sequence	(Figure	S8).	
In	conclusion	the	biophysical	characterization	above	confirms	that	vascin	is	
an	amyloidogenic	peptide	that	readily	forms	b-structured	soluble	oligomeric	
aggregates	that	mature	into	cross-b	structured	amyloid	fibrils	in	a	broad	
concentration	range.		
	
Vascin	inactivates	VEGFR2	in	HUVEC	cells	by	specifically	inducing	its	aggregation	
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As	vascin	is	an	amyloidogenic	peptide	derived	from	a	VEGFR2	fragment	we	
investigated	whether	it	displays	biological	activity	towards	VEGFR2	in	cultured	cells.	
First,	we	monitored	cellular	uptake	of	vascin	using	carboxyfluorescein	labelled	
vascin	(CF-vascin)	in	HUVEC	cells.	We	observed	cellular	uptake	during	the	first	hour	
of	incubation	as	small	vesicles	or	inclusions	that	contained	diffuse	homogeneous	
peptide	(Figure	2A).	Moreover,	these	inclusions	were	positive	for	the	amyloid	sensor	
dye	pFTAA	(Figure	2B&C),	showing	that	the	peptide	remains	in	an	amyloid-like	
conformation	inside	the	cells.	Co-staining	for	the	ER	protein	Calnexin	reveals	that	the	
peptides	are	on	the	cytoplasmic	side	of	the	ER	(Figure	2D),	where	they	partially	
overlaps	with	staining	for	ribosomes	(Figure	2E).	Proximity	ligation	(Duo-Link)	using	
antibodies	against	VEGFR2	and	the	carboxyfluorescein-label	on	vascin	(Figure	2F),	
quantified	by	image	analysis	from	high	content	microscopy	demonstrated	direct	
interaction	between	vascin	and	VEGFR2	(Figure	2G).		This	result	was	further	
confirmed	by	two	color	direct	stochastic	optical	reconstruction	microscopy	
(dSTORM)	super-resolution	imaging(37)	using	0.5µM	of	Alexa647	labeled	vascin	and	
Alexa568	labeled	immunodetection	of	VEGFR2	(Figure	2H&I).		
Co-immunoprecipitation	of	VEGFR2	from	lysates	of	vascin-treated	HUVECs	
was	performed	with	PEG-biotin	labeled	peptide	again	demonstrating	direct	
interaction	between	vascin	and	VEGFR2	(Figure	3A).	To	investigate	the	
consequences	of	the	interaction	between	vascin	and	VEGFR2	on	the	aggregation	
status	of	the	receptor,	we	determined	the	difference	in	distribution	of	VEGFR2	
between	soluble	and	insoluble	fractions	of	lysates	from	HUVECs	treated	with	20	µM	
of	vascin.	Upon	vascin	treatment	we	could	observe	a	clear	redistribution	of	full	
length	and	partially	degraded	VEGFR2	towards	the	insoluble	fraction	whereas	this	
was	not	the	case	upon	treatment	with	scrambled	vascin	(Figure	3B).	In	addition,	the	
induced	insoluble	VEGFR2	displays	partial	resistance	to	the	ionic	detergent	SDS,	a	
hallmark	of	amyloid-like	aggregation	(Figure	3C).	To	confirm	that	vascin	mediated	
aggregation	of	VEGFR2	in	HUVECs	leads	to	its	loss-of-function	we	determined	the	
dose	response	curve	of	vascin	on	VEGFR2	autophosphorylation	and	ERK	
phosphorylation	(MSD	ELISA	assay)	after	stimulating	HUVECs	for	5	min	with	1.3	nM	
VEGF.	HUVECs	displayed	a	clear	dose	responsive	inhibition	by	vascin	with	an	IC50	of	
6.8	±	0.5	µM	for	receptor	autophosphorylation	and	8.3	±	0.4	µM	for	ERK	
phosphorylation	(Figure	3D&E).	The	human	version	of	vascin	showed	similar	
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inhibition,	which	was	not	observed	using	the	scrambled	or	proline	controls	(Figure	
3F).	Using	fluorescence-activated	cell	sorting	(FACS)	we	observed	a	concomitant	
reduction	in	the	surface	expression	of	VEGFR2	in	HUVECs,	but	not	of	the	unrelated	
cell-surface	protein	CD29	(Figure	3G	&	Figure	S9),	confirming	loss	of	VEGFR2	
function	in	HUVECs.	Together	these	data	show	that	vascin	is	internalized	by	HUVECs	
and	reaches	the	cytoplasmic	compartment	where	it	directly	binds	to	VEGFR2	and	
localizes	with	ribosomes,	resulting	in	the	functional	inactivation	through	aggregation	
of	VEGFR2.	This	effect	seemed	to	be	specific	as	indicated	by	the	CD29	result.	
Moreover,	we	observed	no	effect	of	vascin	on	EGF	signalling	in	HeLa	cells,	which	do	
not	endogenously	express	VEGFR2	but	the	functionally	homologous	EGFR.	
Threatment	of	this	cell	line	with	20	µM	vascin	showed	no	inhibition	of	ERK	
phosphorylation	when	stimulated	with	EGF	(Figure	3H),	showing	that	the	inhibitory	
effect	of	vascin	on	ERK	phosphorylation	is	specific	for	VEGFR2	stimulation.	To	test	if	
known	amyloidogenic	proteins	were	affected	by	vascin,	we	investigated	the	effect	of	
adding	vascin	to	solutions	of	the	Alzheimer	b-peptide	1-42	(Ab,	Figure	3I)	or	the	
human	Prion	protein	(PrP,	Figure	3J)	and	monitored	aggregation	through	ThT	
fluorescence	emission.	The	mean	lag	time	for	unseeded	aggregation	of	Aβ1-40	was	
350	minutes	whereas	addition	of	preformed	Aβ	fibrils	decreased	the	lag	time	to	130	
minutes.	Addition	of	vascin	fibril	variants	did	not	lead	to	significant	decrease	of	
fibrillation	lag	times	other	than	for	scrambled	vascin	where	the	significance	level	in	a	
paired	T-test	was	p>0.03.	The	mean	lag	time	for	spontaneous	conversion	of	
HuPrP23-231	was	1100	minutes.	The	conversion	rate	upon	addition	of	preformed	
HuPrP90-231	fibrils	was	shortened	to	135	minutes	whereas	addition	of	preformed	
vascin	fibril	variants	did	not	lead	to	significant	alteration	of	lag	time.	These	data	
demonstrate	that	no	vascin	cross-seeding	occur	for	these	proteins.	
	
Vascin	reduces	VEGFR2-dependent	tumor	growth	in	mice	
To	establish	the	effect	of	vascin	in	vivo	we	turned	to	a	functional	angiogenesis	model	
that	is	sensitive	to	inhibition	of	VEGFR2	in	vivo	and	used	a	subcutaneous	B16	
melanoma	syngenic	tumor	model	in	C57BL/6	inbred	mice.	Tumor	growth	of	this	line	
is	strongly	reduced	by	VEGFR2-specific	inhibition	approaches,	such	as	the	tyrosine	
kinase	inhibitor	PTK	787/ZK	222584	(38),	providing	a	sensitive	phenotypic	readout	
for	the	anticipated	effect	of	vascin.	To	assess	if	vascin	administration	would	be	
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tolerated	by	C57BL/6	mice	we	first	performed	a	dose-escalation	study	by	daily	
intravenous	(iv)	tail	vein	injection	in	two	six-week-old,	inbred	C57BL/6	mice,	
starting	from	1	mg/kg	to	10	mg/kg	biotin-PEG	vascin,	which	corresponded	to	the	
highest	stock	concentration	of	the	peptide	that	we	could	reach	with	the	available	
material.	No	adverse	effects	to	the	basic	physiological	and	behavioral	parameters	of	
the	animals	were	apparent	across	this	concentration	range,	including	body	weight,	
food	and	water	consumption,	home	cage	activity	and	locomotion.	To	test	the	effect	of	
vascin	on	tumor	growth,	B16	cells	were	injected	subcutaneously	in	the	right	dorsal	
flank	of	eight-week-old	C57BL/6	mice.	Starting	from	three	days	post	tumor	injection	
and	until	day	17,	mice	were	treated	daily	by	iv	injection	of	10	mg/kg	biotin-PEG	
vascin	(N=10)	or	scrambled	vascin	as	the	negative	control	(N=10).	Another	negative	
control	group	received	iv	injection	of	the	vehicle	(50	mM	Tris	HCl	pH7.5,	N=10)	and	
the	positive	control	group	(N=5)	received	the	kinase	inhibitor	PTK787	orally	
(75mg/kg).	Tumor	growth	was	similar	in	animals	treated	with	scrambled	vascin	or	
vehicle,	and	markedly	reduced	in	animals	that	received	the	PTK	inhibitor.	In	the	
vascin	treated	group	tumor	growth	was	significantly	inhibited	compared	to	the	
negative	controls	over	the	entire	experiment	(ANOVA	with	Tukey	post-hoc)	and	up	
to	day	14	to	a	similar	extent	as	the	PTK	treated	group	(Figure	4A).	
In	order	to	exclude	overall	toxicity	effects	of	vascin	on	the	general	physiology	of	the	
mouse,	we	executed	a	short	term	toxicology	study	in	which	we	treated	groups	of	5	
mice	daily	with	iv	injections	of	vascin	(10	mg/kg,	group	A),	scrambled	(10	mg/kg,	
group	B)	or	vehicle	(50	mM	Tris	pH	7.5)	for	14	days	(the	same	duration	as	the	tumor	
growth	experiment).	Gross	examination	at	necropsy	did	not	reveal	any	macroscopic	
changes	(Figure	S10A).	Concerning	organ	weights	(Figure	S10B),	hematology	(Figure	
S10C)	and	clinical	chemistry	(Figure	S10D),	no	statistically	significant	differences	
were	observed	among	groups.	Also	no	significant	variations	were	observed	among	
the	experimental	groups	in	terms	of	lesion	spectrum,	frequency	and	severity.	In	
addition,	we	examined	brain	sections	from	all	the	animals	for	amyloid	deposition	and	
associated	astrogliosis.	Thioflavin-S-positive	deposits	in	the	brain	parenchyma	were	
not	detected	(Figure	S11	A,	B	&	C)	and	co-staining	with	GFAP	(glial	fibrillary	acidic	
protein)	did	not	show	any	morphological	evidence	of	astrogliosis,	in	sharp	contrast	
to	the	positive	control	(Figure	S11D),	for	which	we	employed	a	transgenic	Alzheimer	
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disease	mouse	model	that	has	marked	amyloid	deposition	throughout	the	cortex	and	
hippocampus	(39).		
	 In	order	to	demonstrate	the	arrival	and	presence	of	vascin	at	the	tumor	site,	
two	groups	of	tumor-bearing	mice	were	injected	iv	with	10	mg/kg	CF-vascin	or	
vehicle	(50mM	Tris	HCl	pH	7.5,	negative	control)	and	imaged	with	whole-body	
fluorescence	imaging.	Because	the	melanin-expression	by	the	tumors	strongly	
absorbs	light	hampering	the	in	vivo	detection	of	fluorescence,	tumors	were	isolated	
30	min	after	injection	and	imaged	ex	vivo.	The	resulting	fluorescence	images	showed	
strong	green	fluorescence	emission	for	tumors	isolated	from	CF-vascin-injected	mice,	
whereas	no	fluorescence	could	be	detected	from	tumors	isolated	from	vehicle-
injected	control	mice	(Figure	S12A),	supporting	the	presence	of	vascin-CF	at	the	
tumor	site	based	on	macroscopic	CF-fluorescence	measurements.		To	further	verify	
the	presence	of	CF-vascin	inside	the	tumor	tissue	with	microscopic	resolution,	we	
additionally	examined	the	presence	of	CF-vascin	with	Fibered	Confocal	Fluorescence	
Microscopy	(FCFM)	on	tumor	samples	from	the	same	mice.		Inserting	the	fibre-
optical	probe	inside	the	tumor	tissue	sample	of	vehicle-injected	control	mice	did	not	
show	any	fluorescence	signal,	whereas	the	tumor	samples	of	CF-vascin-injected	mice	
were	clearly	positive	for	green	fluorescence	(Figure	S12B).	To	quantify	vascin	in	B16	
tumors,	the	specific	light	absorption	by	melanomas	was	calibrated	through	the	
addition	of	different	known	quantities	of	CF-vascin	to	series	of	tumor	tissue	dilutions	
and	compared	to	a	standard	curve	of	fluorescence	intensity	for	a	dilution	series	of	
pure	CF-vascin.		Both	were	found	to	be	linear	in	a	large	concentration	range	and	for	
two	different	fluorescence	imaging	modalities,	thereby	cross-validating	the	results	
(Figure	S13A&B).	The	tumor-specific	fluorescence	attenuation	was	then	used	to	
estimate	the	concentration	of	CF-vascin	in	tumors	isolated	from	CF-vascin-treated	
mice,	which	was	established	to	be	26.4	±	10.5	µM,	a	concentration	that	is	well	above	
the	IC50.		
Taken	together	these	data	are	consistent	with	a	direct	inhibitory	activity	of	vascin	on	
VEGFR2	function	in	vivo	in	the	same	manner	that	was	observed	in	cells.	
	
Amyloid	toxicity	is	conditional	to	VEGFR2	dependence	of	cells	
We	determined	loss	of	VEGFR2	function	and	vascin	amyloid	toxicity	in	several	
cell	lines.	CellTiter-Blue	cytotoxicity	assays	(Figure	4B)	revealed	that	in	HUVECs	loss	
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of	function	of	the	receptor	(IC50	of	6.8	±	0.5	µM	for	receptor	autophosphorylation	and	
8.3	±	0.4	µM	for	ERK	phosphorylation)	goes	hand	in	hand	with	cytotoxicity.	On	the	
other	hand	in	HEK293	or	U2OS	cells	neither	2.5-100	µM	of	vascin	or	its	scrambled	
counterpart	were	found	to	be	toxic	(Figure	4C&D).	Upon	transfection	of	VEGFR2	in	
HEK293	we	observed	that,	after	VEGF	stimulation,	ERK	phosphorylation	was	
inhibited	upon	treatment	with	20	µM	vascin	(Figure	S14A)	which	induced	the	
aggregation	of	the	VEGFR2	as	evidenced	on	the	fractionation	assay	(Figure	S14B).	
However,	no	noticeable	toxicity	of	vascin	to	HEK293	cells	expressing	VEGFR2	was	
observed	in	the	range	of	2.5	-	100	µM	(Figure	4E).	This	demonstrates	that	vascin	is	
not	toxic	to	HEK293	cells	in	the	absence	of	VEGFR2	but	also	that	aggregation	of	
transiently	expressed	VEGFR2	in	these	lines	does	not	affect	cell	viability.	Similar	
observations	were	made	with	U2OS	cells	expressing	VEGFR2	(Figure	4F).	Thus	
vascin	does	not	display	generic	amyloid	toxicity	and	the	aggregation	of	VEGFR2	by	
vascin	is	in	itself	also	not	toxic.	Finally,	as	neurons	are	particularly	sensitive	to	
aggregate	toxicity	we	assessed	the	toxicity	of	vascin	to	primary	cortical	neurons,	
which	do	not	express	VEGFR2.	Although	with	these	neurons	we	observed	significant	
toxicity	upon	peptide	treatment	(Figure	4G),	CellTiter-Blue	reaction	levels	were	
similar	for	the	vascin	and	its	scrambled	non-amyloid	variant,	suggesting	that	the	
toxicity	was	not	amyloid-specific	but	rather	reflects	the	high	sensitivity	of	these	
cultures,	which	also	resulted	in	a	large	variability	in	the	assay.	To	verify	this	further	
we	turned	to	human	iPSCs	differentiated	to	a	cortical	neuronal	phenotype,	which	was	
verified	using	q-RT-PCR	and	immunostaining	for	markers	specific	for	this	cell	type	
(Figure	S15).	In	these	cultures	we	observed	a	lack	of	amyloid-specific	toxicity,	
although	there	is	10%	toxicity	associated	with	administration	of	both	vascin	or	the	
scrambled	control	(Figure	4H).	
	 Together	these	data	suggest	that	amyloid	toxicity	is	not	dependent	on	cell	
type	or	even	on	target	protein	aggregation	but	that	amyloid	toxicity	is	mainly	
determined	by	the	biological	context	in	which	the	target	protein	is	inactivated	by	
aggregation.	As	HUVEC	survival	is	dependent	on	VEFGR2	function,	its	molecular	loss	
of	function	by	aggregation	translates	in	gain	of	toxic	phenotype.	
	
DISCUSSION	
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About	thirty	amyloidogenic	proteins	are	known	to	contribute	to	human	disease.	
These	diseases	include	neurodegenerative	diseases	such	as	Alzheimer’s	or	
Parkinson’s	disease	but	also	organ-specific	and	systemic	amyloidosis	such	as	
diabetes	mellitus	type-2	or	light	chain	amyloidosis(7).	Although	the	
pathophysiological	profiles	of	these	diseases	are	disparate,	involving	the	aggregation	
of	different	proteins,	affecting	distinctive	cell	types	or	tissues	and	having	very	
different	progression	rates,	they	also	share	common	structural,	biochemical	and	
biological	features	suggesting	that	amyloids	might	also	have	similar	modes	of	
interaction	with	cellular	components(8).	Although	amyloids	of	different	proteins	
have	been	shown	to	interact	with	lipids(40),	proteins(41)	and	nucleic	acids(42),	it	is	
currently	unclear	which	of	these	interactions	are	relevant	for	disease.	While	some	
amyloid	interactions	are	rather	unspecific,	e.g.	with	biological	lipids(43)	other	
amyloid	interactions	are	highly	specific(20).	The	most	prominent	of	these	is	the	self-
interaction	of	amyloidogenic	sequences	during	amyloid	fibril	formation	which	
includes	both	amyloid	nucleation	and	fiber	elongation(44,	45).	Proteome	wide	
studies	using	amyloid	prediction	algorithms	suggest	that	most	proteins	possess	
amyloidogenic	sequence	segments	within	their	structure	even	though	they	do	not	
form	amyloid	under	normal	conditions(5,	6).	Given	the	sequence	specificity	of	
amyloid	seeding	this	suggests	that	amyloid	aggregation	should	be	specifically	
inducible	in	non-amyloid	associated	proteins	by	exposing	them	to	amyloidogenic	
peptides	derived	from	their	own	sequence.	
	
Here	we	demonstrate	that	aggregation	of	endogenously	expressed	VEGFR2	
can	be	induced	under	physiological	conditions	by	exposing	it	to	vascin,	a	peptide	
consisting	of	a	tandem	repeat	of	an	amyloidogenic	sequence	in	its	signal	peptide.	We	
find	that	vascin	possesses	all	attributes	of	natural	amyloids	including	cross-beta	
structure,	the	population	of	amyloid	precursor	aggregates,	and	the	ability	to	reach	
the	cytoplasmic	compartment	of	cells,	confirming	that	the	signal	peptide	of	VEGFR2	
possesses	a	genuine	amyloidogenic	sequence.	In	addition	we	find	that	vascin	is	able	
to	induce	VEGFR2	aggregation	by	direct	interaction	with	VEGFR2.	As	vascin	is	
targeting	the	VEGFR2	signaling	peptide,	seeding	of	VEGFR2	aggregation	is	likely	to	
be	co-translational	as	suggested	by	ribosomal	colocalization	of	vascin	in	the	
cytoplasm	and	the	occurrence	of	partial	VEGFR2	degradation	along	with	its	
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aggregation.	This	results	in	VEGFR2	inactivation	in	vitro	but	also	in	vivo	where	it	
inhibits	VEGFR2	dependent	tumor	growth	upon	intravascular	administration.	Both	
the	aggregation	as	well	as	the	inhibition	of	VEGFR2	appears	to	be	specific.	Indeed,	
scrambled	vascin	or	the	proline	mutant	do	not	interact	with	VEGFR2,	nor	does	it	
provoke	VEGFR2	aggregation	or	inhibition.	In	addition,	whereas	vascin	suppresses	
cell	surface	presentation	of	VEGFR2,	it	does	not	affect	trafficking	of	other	receptors	
such	as	CD29	or	EGFR.	Finally,	vascin-induced	VEGFR2	aggregation	is	not	inherently	
toxic	as	it	does	not	affect	the	viability	of	VEGFR2	overexpressing	HEK293	cells.	
Together	these	findings	show	that	VEGFR2,	a	protein	not	associated	with	amyloid	
disease,	can	be	specifically	induced	to	aggregate	in	the	presence	of	specific	amyloid	
seeds	that	are	derived	from	its	own	sequence.		
There	may	be	multiple	reasons	why	large	scale	amyloidosis	is	not	observed	
under	natural	conditions	despite	the	likely	prevalence	of	potentially	amyloidogenic	
sequences	in	many	proteins.	First,	most	amyloidogenic	sequences	are	buried	in	
globular	protein	domains,	which	is	probably	the	main	protective	factor	against	
amyloidosis(46).	Moreover,	most	misfolded	proteins	will	be	actively	degraded	in	the	
cell	before	they	have	the	opportunity	to	aggregate(47).	Secondly,	even	in	unfolded	or	
intrinsically	disordered	proteins	most	amyloidogenic	sequences	are	generally	still	
sufficiently	protected	from	aggregation	by	structural	mechanisms	such	as	
gatekeeping(48)	(i.e.	the	inhibition	of	aggregation	by	charged	residues	adjacent	to	
the	amyloidogenic	segment)	and	entropic	bristles(49)	(i.e.	unstructured	protein	
segments	that	entropically	prevent	the	association	of	amyloidogenic	sequences).	
Finally	interaction	with	molecular	chaperones	will	also	contribute	to	the	inhibition	of	
aggregation(50).	The	reason	why	vascin	can	overcome	these	potential	protective	
mechanisms	is	not	yet	clear	but	might	reside	in	its	design:	vascin	comprises	a	tandem	
repeat	of	an	amyloidogenic	sequence,	which	exacerbates	the	aggregation	propensity	
of	this	sequence	and	leads	to	the	formation	of	soluble	and	stable	oligomeric	
aggregates,	and	these	are	likely	to	provide	efficient	sites	for	seeding.	Incidentally,	
yeast	prions	often	consist	of	peptide	sequence	repeats(32)	and	the	stability	of	
soluble	oligomers	consisting	of	tandem	peptide	repeats	recently	allowed	their	
structure	solvation	by	X-ray	crystallography(29).		
The	toxic	gain-of-function	observed	in	many	amyloid-associated	diseases	
remains	poorly	explained.	This	is	mainly	due	to	the	impossibility	to	relate	loss-of-
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function	effects	to	the	aggregation	process	of	a	given	protein.	Indeed	for	many	
amyloid	proteins,	especially	in	neurodegeneration,	the	functional	role	of	the	affected	
protein	is	often	complex	and	not	entirely	understood(25,	26),	which	makes	it	difficult	
to	unequivocally	identify	loss-of-function	effects.	In	addition	the	interactions	of	
amyloid	with	cellular	components	in	disease	is	also	not	clarified	so	that	again	gain-
of-toxic	function	is	not	directly	tractable	at	the	molecular	level.	The	availability	of	our	
artificial	amyloid	model	provides	an	opportunity	to	study	the	relationship	between	
amyloid	toxicity	and	specific	protein	loss-of-function.	Indeed	while	recapitulating	
essential	amyloid	features	our	model	also	allows	to	monitor	the	effect	of	amyloidosis	
on	a	functionally	well-characterized	protein.	Moreover,	the	use	of	a	VEGFR2	
fragment	allows	assessing	amyloid	toxicity	independently	of	VEGFR2	function.		
Our	results	demonstrate	that	using	this	setup	vascin	does	not	display	generic	
toxic	properties	but	rather	to	the	contrary.	Vascin	gain-of-function	is	specific	(i.e.	it	is	
dependent	on	the	presence	of	VEGFR2)	but	also	conditional	(i.e.	VEGFR2	needs	to	be	
expressed	in	the	cell	but	the	cell	also	needs	to	be	dependent	on	VEGFR2	for	its	
survival/proliferation).	Indeed	in	VEGFR2	dependent	HUVECs	vascin	toxicity	and	
VEGFR2	loss-of-function	correlate	in	a	dose-responsive	manner	whereas	this	is	not	
the	case	in	VEGFR2	expressing	HEK293	cells.	Together	these	results	therefore	
illustrate	how	amyloid	toxicity	can	result	from	a	conjunction	of	protein	specific	and	
cell	dependent	protein	loss-of-function.	Whether	lack	of	generalized	toxicity	is	
coupled	to	the	availability	of	specific	‘aggregation	epitopes’	during	or	after	
translation	remains	to	be	further	explored.	It	is	possible	that	only	selected	APRs,	
occuring	in	the	right	structural	context,	would	be	sensitive	to	co-aggregation.	
However,	the	results	in	other	model	systems,	such	as	plants	(31)	and	bacteria	(30),	
suggest	that	this	not	the	most	likely	scenario,	but	that	the	selectivity	comes	from	the	
seqeunce	specificity	of	the	amyloid	interaction	(20,	51).	Further	studies	are	needed	
to	clarify	this	point.	
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Materials	and	Methods	
Bioinformatics	
We	used	the	TANGO	algorithm	for	all	APR	identifications	in	this	manuscript.	We	used	
a	cutoff	on	the	TANGO	score	of	5	per	residue	since	this	gives	a	Mathews	Correlation	
Coefficient	between	prediction	and	experiment	of	0.92(28).	The	settings	of	TANGO	
were	Temperature	=	298K,	pH	=	7.5,	Ionic	Strength	=	0.10	M.	
		
Peptides		
Peptides	were	synthesized	in-house	using	an	Intavis	Multipep	RSi	synthesis	robot.	
Raw	peptides	were	stored	as	dry	ether	precipitates	at	-20	°C	prior	to	use.	Purified	
peptides	where	lyophilized	and	closed	under	nitrogen	atmosphere	and	stored	at	-20	
°C	prior	to	use.	Stock	solutions	of	each	peptide	were	prepared	fresh	in	1%	w/v	
ammonium	bicarbonate	in	MiliQ	water,	filtered	through	0.22	μm	regenerated	
cellulose	filter	(Whatman,	USA)	and	used	immediately.	The	concentration	of	the	
peptides	stocks	was	determined	by	absorbance	at	280	nm	using	the	calculated	molar	
extinction	coefficient	ε=11380	M-1cm-1.	
	
Cell	lines	and	media	
HUVEC	cells	(Lonza)	were	grown	in	EGM2	complete	medium	(Lonza)	in	flasks	pre-
coated	with	0.1%	gelatin.	The	cells	were	never	allowed	to	grow	confluent	and	were	
only	used	for	experiments	between	passage	p3	and	p9.	U2-Os	and	HEK293	cells	were	
maintained	in	DMEM	medium,	supplemented	with	10%	FBS,	1	mM	sodium	pyruvate,	
non-essential	amino	acids	and	antibiotics	(penicillin/streptomycin).	Lipofectamine	
2000	(Life	Technologies)	was	used	to	transiently	transfect	HEK293	and	U2OS	cells	
with	an	expression	vector	for	VEGFR2	(pCDNA3)	generating	the	cell	lines	
HEK293VEGFR2	and	U2OSVEGFR2.	All	peptide	treatments	were	done	in	DMEM/F12	
medium	without	additives.	Toxicity	of	the	peptide	treatments	was	evaluated	using	
the	CellTiter-Blue	Cell	Viability	Assay	according	to	the	instructions	of	
the	manufacturer	(Promega,	USA).	
	
Quantification	of	growth	factor	signaling	
HUVEC,	HEK293,	U2OS,	HEK293VEGFR2	and	U2OSVEGFR2	cells	were	treated	with	peptide	
overnight.	The	next	day	cells	were	stimulated	with	25	ng/ml	recombinant	mouse-
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VEGF	(493-MV,	R&D	Systems)	or	recombinant	human-EGF	(236-EG,	R&D	Systems)	
for	exactly	5	min	at	37°C.	Cells	were	washed	twice	with	ice	cold	PBS	and	lysed	in	
RIPA	lysis	buffer	(ThermoFisher	Scientific)	supplement	with	Complete	protease	
inhibitor	(Roche)	and	PhosSTOP	phosphatase	inhibitor	(Roche).	Quantification	of	
VEGFR2	autophosphorylation	and	ERK	phosphorylation	was	performed	by	
electrochemiluminescence	ELISA	using	the	following	kits	according	to	the	
manufacturer’s	recommended	protocol:	Phospho-VEGFR-2(Tyr1054)	(K151DJD,	
Meso	Scale	Discovery)	and	Phospho(Thr202/Tyr204;	Thr185/Tyr187)/Total	
ERK1/2	(K15107D,	Meso	Scale	Discovery).	
	
X-ray	fiber	diffraction	
X-ray	fiber	diffraction	samples	were	made	by	allowing	a	droplet	of	the	stock	fibril	
solution	to	dry	between	two	wax	tipped	capillary	tubes.	X-ray	diffraction	data	was	
collected	using	a	Rigaku	rotating	anode	(CuKa)	with	Saturn	CCD	detector	with	
exposure	times	of	30-60	seconds	and	specimen	to	detector	distance	of	50	or	100	mm.	
Reflections	were	measured	using	CLEARER	(52).	
	
In	vivo	experiments	
All	animal	procedures	were	approved	by	the	local	animal	ethical	committee.	Female	
C57BL/6		mice,	8	weeks	of	age,	were	purchased	from	Janvier	(France).	The	B16.F10	
melanoma	cell	line	was	obtained	from	the	American	Type	Culture	Collection	(ATCC)	
and	maintained	in	Dulbecco's	Modified	Eagle's	Medium	(DMEM)	supplemented	with	
10%	fetal	bovine	serum.	B16	cells	(5x105	cells/mouse)	were	implanted	
subcutaneously	in	the	right	dorsal	flank	of	C57BL/6	mice.	Starting	from	3	days	after	
tumor	implantation,	mice	were	randomized	in	three	groups	and	treated	daily	by	
intravenous	delivery	of	vascin	or	scrambled	vascin	(10mg/kg),	or	by	oral	delivery	of	
PTK787	(75mg/kg).	Tumors	growth	was	monitored	by	caliper	measurement	every	
2–3	days	starting	from	10	days	after	tumor	injection.	The	experiment	had	10	animals	
per	group	at	onset,	except	the	PTK	group,	which	had	five.		
	
Transmission	Electron	Microscopy	(TEM)	
For	each	sample	7	µL	aliquots	of	peptide	solution	were	adsorbed	for	1	minute	to	
formvar	film	coated	copper	grids	of	400-mesh	(Agar	Scientific	Ltd.,	England)	that	
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were	first	glow	discharged	to	improve	adsorption.	After	sample	adsorption	grids	
were	washed	by	contact	with	5	drops	of	ultrapure	water	and	stained	by	contact	with	
one	drop	of	uranyl	acetate	(2%	w/v	in	MiliQ	water)	for	45	sec.	The	grids	were	
examined	using	a	JEM-2100	transmission	electron	microscope	(Jeol,	Japan)	at	80	
keV.	
	
Biophysical	characterization	
Dynamic	light	scattering	(DLS)	measurements	were	made	at	room	temperature	with	
a	DynaPro	DLS	plate	reader	instrument	(Wyatt,	Santa	Barbara,	CA,	USA)	equipped	
with	a	830-nm	laser	source.	Samples	(100	μL	300	µM	peptide	stock)	were	placed	
into	a	flat-bottom	96-well	microclear	plate	(Greiner,	Germany).	The	autocorrelation	
of	scattered	light	intensity	at	a	90°	angle	was	recorded	for	10	s	and	averaged	over	40	
recordings	to	obtain	a	single	data	point.	The	Wyatt	Dynamics	software	was	used	to	
calculate	the	hydrodynamic	radius	by	assuming	linear	polymer	particles.	Attenuated	
Total	Reflection	Fourier	Transform	Infrared	Spectroscopy	(ATR	FTIR)	was	
performed	using	a	Bruker	Tensor	27	infrared	spectrophotometer	(Bruker,	Germany)	
equipped	with	a	Bio-ATR	II	accessory	(Harrick	Scientific	Products,	USA).	Spectra	
were	recorded	in	the	range	of	900	–3500	cm-1	at	a	spectral	resolution	of	2	cm-1	by	
accumulating	256	data	acquisitions.	The	spectrophotometer	was	continuously	
purged	with	dried	air.	Spectra	were	corrected	for	atmospheric	water	vapor	
interference,	baseline-subtracted,	and	vector	normalized	in	the	amide	II	area	(1500	
to	1600	cm-1)	as	implemented	in	OPUS	software	(Bruker).	Tinctorial	analysis	was	
performed	by	incubating	vascin	or	its	scrambled	version	at	the	concentration	
indicated	on	each	figure	with	20	µM	ThT,	20	µM	ANS	or	0.3	µM	h-HTAA	and	
fluorescence	emission	was	recorded	in	a	PolarStar	Optima	plate	reader	(BMG	
labtech,	Germany)	equipped	with	360	nm	and	490	nm	excitation	filters	and	460	nm	
and	520	nm	emission	filters.	All	filters	had	10	nm	band-pass.	Emission	fluorescence	
spectra	of	h-HTAA	bound	to	vascin	or	scrambled	vascin	were	recorded	in	a	
FlexStation	3	(Molecular	Devices,	USA)	at	the	same	concentration	of	peptide	and	
fluorophore	listed	above,	with	excitation	at	480	nm	and	emission	recorded	between	
490	nm	and	620	nm	using	10	nm	band-pass.	
	
Statistics	
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Statistical	analysis	was	performed	using	Prism,	Origin	or	R.	Unpaired	student’s	t-test	
and	anova	were	used	to	determine	significant	differences	between	samples	unless	
otherwise	indicated.	Significance	levels:	*	for	p	<0.05,	**	for	p	<0.01,	***	for	p	<	0.001.	
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Figure	Legends	
Figure	1	–	Biophysical	characterization	of	the	amyloids	formed	by	vascin.	(A-D)	
Transmission	Electron	Microscopy	image	of	300	µM	vascin	in	1%	(w/v)	NH4CO3	after	
24h	incubation	at	room	temperature	and	negatively	stained	with	2%	(w/v)	uranyl	
acetate.	(E)	Tinctorial	analysis	of	fibrils	of	300	µM	vascin	in	1%	(w/v)	NH4CO3	after	
18h	incubation	at	room	temperature.	The	bars	show	the	mean	of	3	measurements	
and	the	error	bars	show	the	standard	deviation.	(F)	Fiber	x-ray	diffraction	pattern	of	
fibrils	formed	in	300	µM	vascin	in	1%	(w/v)	NH4CO3.	(G)	ESI–IMS–MS	Driftscope	
plot	of	the	vascin	monomer	(1)	through	to	the	heptamer	(7)	present	two	minutes	
after	diluting	the	monomer	to	a	final	peptide	concentration	of	100	μM	in	in	1%	(w/v)	
NH4CO3.	ESI–IMS–MS	Driftscope	plots	show	the	IMS	drift	time	versus	mass/charge	
(m/z)	versus	intensity	(z,	square-root	scale).	(H)	Histogram	of	size	distribution	of	
particles	calculated	from	the	DLS	data	recorded	during	vascin	aggregation	using	a	
linear	polymer	as	particle	model.	(E)	FT-IR	Spectrum	of	300	µM	vascin	in	1%	(w/v)	
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NH4CO3	at	t=	5	min	(red)	and	t=	24h	(blue).	(J)	Time	progression	of	the	intensity	of	
the	absorbtion	peak	in	the	FT-IR	spectrum	in	panel	E	around	1622	cm-1.	
	
Figure	2	–	Vascin	directly	interacts	with	VEGFR2	in	cells	(A)	Cellular	distribution	
CF-vascinK11	(green)	at	1	µM	in	HUVEC	cells.	(B)	Overlay	between	the	fluorescence	of	
Alexa647-labeled	vascinK11	(20	µM,	red)	and	the	amyloid	specific	dye	pFTAA	(15	µM,	
green).	Overlap	is	shown	as	yellow	colouring.	(C)	Equivalent	image	as	B	for	the	
proline	mutant	of	vascin.	(D)	HUVEC	cells	treated	for	4	hours	with	CF-vascinK11	(2.5	
µM,	green)	and	co-immunostained	for	the	ER-specific	marker	calnexin	(red).	(E)	
HUVEC	cells	treated	for	4	hours	with	CF-vascinK11	(5.0	µM,	green)	and	co-
immunostained	for	the	ribosomal	protein	S6	(red).	(F)	Proximity	ligation	(Duo-Link)	
between	CF-vascinK11	at	5.0	µM	and	VEGFR2	performed	in	HUVEC	cells	treated	for	4	
hours	with	peptide.	For	panels	A,	D,	E	and	F	the	nuclei	are	stained	with	DAPI	in	blue.	
(G)	Quantification	of	the	Duo-Link	signal	by	high	content	microscopy	of	HUVEC	cells	
treated	with	vascin	as	depicted	in	(E).	For	each	condition	about	700	cells	were	
analyzed	and	the	average	fluorescence	intensity	per	cell	is	shown.	The	box	shows	the	
interquartile	range	of	the	25	to	75	percentile.	The	line	in	the	middle	of	the	box	
indicates	the	median	and	the	lines	extending	from	the	box	indicate	the	99%	limits	of	
the	distribution.	Outliers	are	shown	as	circles.	(H)	dSTORM	image	of	HUVEC	cells	
treated	for	4	hours	with	0.5	µM	Alexa647-labeled	vascinK11	(purple)	and	co-
immunostained	for	VEGFR2	(green).	Scale	bar	is	1	µm.	(I)	Magnification	of	image	in	G	
where	arrowheads	indicate	the	interaction	of	vascin	and	VEGFR2.	Scale	bar	is	1	µm.		
	
Figure	3	–	Vascin	knocks	down	VEGFR2	activity.	(A)	Western	blot	analysis	for	
VEGFR2	co-immunoprecipitation	in	HUVEC	cells	treated	for	4	hours	with	20	µM	
biotin-PEG	labeled	vascin.	(B)	Western	blot	analysis	of	the	partitioning	of	VEGFR2	
between	the	soluble	and	insoluble	fraction	of	HUVEC	cells	treated	with	20	µM	vascin.	
(C)	Western	blot	analysis	of	the	SDS-gradient	extraction	of	the	soluble	and	insoluble	
fraction	of	HUVEC	cells	treated	with	20	µM	vascin.	(D)	Dose-response	curve	of	the	
effect	of	2.5-100	µM	vascin	on	VEGF	stimulation	of	VEGFR2	autophosphorylation	in	
HUVEC	cells.	The	plot	shows	the	mean	of	three	measurements	and	the	standard	
deviation.	Curve	fitting	was	performed		(E)	Dose-response	curve	of	the	effect	of	2.5-
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100	µM	vascin	on	VEGF	stimulation	of	ERK	phosphorylation	in	HUVEC	cells.	The	data	
is	shown	as	the	mean	of	four	replicates	and	the	standard	deviation.	(F)	VEGFR2	
autophosphorylation	and	ERK	phosphorylation	in	HUVEC	cells	treat	with	20	µM	
vascin,	human	vascin	(h.vascin),	scrambled	vascin	and	proline	mutant	vascin	(Pro).	
The	bars	show	the	mean	of	four	measurements	and	the	error	bars	show	the	standard	
deviation.	(G)	Quantification	by	Fluorescence	Activated	Cell	Sorting	(FACS)	of	the	
fraction	of	1cells	that	display	VEGFR2	and	CD29	on	the	cell	surface	upon	treatment	
with	vascin	or	scrambled	vascin	at	20	µM.	Per	condition	10.000	cells	were	analysed.	
The	bars	show	the	mean	of	three	measurements	and	the	error	bars	show	the	
standard	deviation.	The	star	indicates	a	p-value	<0.05	calculated	by	student-t	test	
compared	to	the	non-treated	condition.	(H)	Quantification	of	ERK	phosphorylation	
level	as	determined	by	MSD	assay	upon	EGF	stimulation	of	HeLa	cells	treated	with	20	
µM	vascin	or	its	scrambled	version.	The	data	is	shown	as	the	mean	of	four	replicates	
and	the	standard	deviation.	(I)	Lag	phase	of	the	aggregation	kinetics	of	the	Alzheimer	
b-peptide	1-40	(Ab1-40)	observed	with	Thioflavin	T	fluorescence	in	the	presence	of	
1%	molar	fraction	of	homotypic	seeds	(self	seed),	or	the	equivalent	amount	of	seeds	
of	vascin,	human	vascin,	scrambled	vascin	or	the	proline	mutant	vascin.	(J)	
Equivalent	experiment	to	panel	I	for	the	human	Prion	protein	(HuPrP23-231).	All	
aggregation	kinetics	experiments	were	run	in	6	replicates	and	the	bars	show	the	
mean	value,	with	error	bars	showing	the	standard	deviation.	The	statistically	
significant	differences	were	identified	using	the	Student	t-test.	
	
Figure	4	–	In	vivo	effect	of	Vascin	and	cell-type	dependent	cytotoxicity.	(A)	
Tumor	growth	curves	of	subcutaneously	inject	B6	melanoma	cells	in	C57BL6	mice	
treated	with	daily	intravenous	injections	of	10	mg/kg	biotin-PEG	vascin	or	its	
scrambled	control.	As	a	positive	control	we	used	the	inhibitor	of	the	VEGFR2	tyrosine	
kinase	activity	PTK787.	The	experiment	had	10	animals	per	group,	except	the	PTK	
group,	which	had	five.	The	average	and	standard	error	of	the	mean	are	shown.	
Statistically	significant	differences	were	identified	using	anova	and	Tukey	multiple	
comparison	testing.	(B-H)	Dose	dependent	toxicity	of	vascin	or	its	scrambled	control	
tested	from	2.5	µM	–	100	µM	by	the	CellTiter-Blue	assay	on	(B)	HUVEC	cells,	(C)	
HEK293	cells,	(D)	U2OS	cells,	(E)	HEK293	cells	transiently	overexpressing	VEGFR2,	
(F)	U2OS	cells	transiently	overexpressing	VEGFR2,	(G)	Cortical	primary	neuron	cells	
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from	mouse	and	(H)	cortical	neuronal	progeny	obtained	from	human	induced	
pluripotent	stem	cells	(iPSCs)	after	a	neuronal	differentiation	protocol.	All	toxicity	
data	is	shown	as	the	mean	of	five	measurements	with	standard	deviations,	except	the	
iPSC	data	which	were	48	replicates.	Statistically	significant	differences	were	
identified	using	anova	and	Tukey	multiple	comparison	testing.	
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